Compare Amcor PLC (AMCR) vs Heron Therapeutics Inc (HRTX) Price & Performance

AMCR trades at $47.24, up 0.28% today, near the analyst consensus price target of $47.00. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.23, beating estimates, with revenue growth driven by the Berry acquisition. Net income margin stands at 3.06%, while the P/E ratio of 38.07 indicates a premium valuation. Recent news highlights strong Q4 earnings and expansion in China.

The outlook for AMCR is cautiously optimistic, supported by consistent earnings beats and strategic expansions. However, elevated valuation metrics and a high RSI pose near-term risks. Investor sentiment is positive with a 64% analyst buy rating, but margin pressures and integration risks from acquisitions warrant monitoring. The stock presents a balanced opportunity with growth catalysts tempered by valuation concerns.

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.